Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. (scientific article)

cites work (P2860)

Q37248131	"It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.
Q43801887	37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2001.
Q50786310	42nd annual meeting of the American Society of Clinical Oncology June 2006, Atlanta, GA.
Q50721805	44th annual meeting of the American Society of Hematology. December 7-10, 2002. Philadelphia, Pennsylvania.
Q43801889	6th European Hematology Association Meeting. Frankfurt, Germany. June 21-24, 2001.
Q42333450	7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.
Q26776480	90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr
Q41961217	A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.
Q90196900	A Case of Rituximab-Induced Acute Thrombocytopenia in a Patient with Splenic Marginal Zone Lymphoma and Chronic Hepatitis C Virus Infection
Q49918596	A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies.
Q37672472	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
Q81518508	A case of interstitial pneumonia induced by rituximab therapy
Q85624158	A case of severe acute hepatitis C and delayed antibody production due to rituximab therapy
Q49177202	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.
Q34403364	A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
Q51760339	A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma.
Q38282674	A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.
Q44915690	A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
Q40561787	A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity
Q48256829	A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.
Q40596850	A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells
Q34124140	A perspective on monoclonal antibody therapy: where we have been and where we are going
Q33431680	A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
Q37265471	A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders
Q35142620	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics
Q36892621	A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Q33905245	A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma
Q36623473	A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer
Q33419840	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Q36696911	A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
Q40464939	A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Q45129280	A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Q34007430	A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma
Q40343878	A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.
Q44048667	A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.
Q30657795	A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments
Q38465823	A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas
Q38664705	A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia
Q43883707	A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma
Q64063666	A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress
Q37588583	A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma
Q38068969	A systematic review of biologics for the treatment of noninfectious uveitis
Q38935953	A visualization method measuring the performance of biomarkers for guiding treatment decisions
Q92526099	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
Q33893934	Adaptive immunity in cancer immunology and therapeutics
Q35210415	Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-hodgkin lymphoma?
Q46642466	Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma
Q80066598	Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma
Q82996883	Administration of rituximab during the first trimester of pregnancy without consequences for the newborn
Q36868712	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Q39950688	Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?
Q39591787	Advances and application of radioimmunotherapy in non-Hodgkin lymphoma
Q34014922	Advances in the systemic treatment of cancers in the elderly.
Q36223614	Advances in the treatment of chronic lymphocytic leukemia
Q84122096	Advances in the treatment of chronic lymphocytic leukemia
Q40812370	Adverse events of monoclonal antibodies used for cancer therapy
Q42908395	Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
Q33875674	Aggressive lymphoma in the elderly
Q35206362	Alemtuzumab therapy in B-cell lymphoproliferative disorders
Q74688327	Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study
Q37477829	An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
Q57556559	An array of immunotherapeutic strategies for B-cell lymphomas
Q30341946	An update on the management of chronic lymphocytic leukaemia.
Q27694769	Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies
Q77962247	Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils
Q53136792	Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Q39157250	Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
Q26775363	Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
Q38824182	Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises
Q37601775	Anti-CD20 monoclonal antibodies: historical and future perspectives
Q79345582	Anti-CD20 monoclonal antibody (rituximab) therapy in a child with refractory chronic autoimmune haemolytic anaemia
Q33999509	Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient
Q34926739	Anti-CD20-based therapy of B cell lymphoma: state of the art.
Q40154012	Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity
Q38981073	Anti-EGFR antibody conjugated organic-inorganic hybrid lipid nanovesicles selectively target tumor cells
Q92021395	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer
Q55364518	Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).
Q77839439	Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice
Q53849407	AntiCD20 monoclonal antibody-based radioimmunotherapy of relapsed chemoresistant aggressive post-transplantation B-lymphoproliferative disorder in heart-transplant recipient.
Q35206351	Antibodies for the treatment of diffuse large cell lymphoma.
Q36695767	Antibodies to CD20 and MHC class II antigen bound to B-lymphoma cells accumulate in shed cytoplasmic fragments
Q92752934	Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats
Q36568856	Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma
Q28216171	Antibody evolution beyond Nature
Q34107825	Antibody immunotherapy for leukemia
Q34589909	Antibody therapy for chronic lymphocytic leukemia
Q78111165	Antibody therapy has arrived. Now where does it fit?
Q80821330	Antibody therapy of lymphoma
Q35109771	Antibody therapy of non-Hodgkin's B-cell lymphoma
Q37605247	Antibody-based therapy of leukaemia
Q73228020	Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes
Q36979111	Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.
Q36695677	Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
Q61804097	Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
Q34293689	Application of quantitative pharmacology in development of therapeutic monoclonal antibodies
Q37532286	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment.
Q43602308	Assessment of prognostic factors in follicular lymphoma patients
Q36560317	Auger radiation targeted into DNA: a therapy perspective
Q33769671	Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma
Q73274599	Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival
Q34526368	Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma
Q37742624	Autologous transplant of follicular lymphoma in the era of rituximab
Q35216310	B cell depletion therapy in systemic lupus erythematosus
Q36165319	B cell non-Hodgkin's lymphoma: rituximab safety experience
Q37586921	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
Q35553501	B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience
Q36451422	B cell-targeted therapy for rheumatoid arthritis: an update on the evidence
Q29620717	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
Q56897632	B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses
Q38097129	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design
Q50569687	B-cell depletion in the treatment of mixed cryoglobulinemia.
Q42603286	B-cell-targeted therapy for systemic lupus erythematosus
Q38755075	Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor
Q34526397	Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma
Q35052538	Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
Q33342904	Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy
Q37820097	Beyond chemotherapy: new agents for targeted treatment of lymphoma
Q37738620	Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
Q37244715	Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
Q37635011	Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease
Q37842484	Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies
Q37984565	Biological agents for the treatment of uveitis
Q24685049	Biological response modifiers in cancer
Q38034939	Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma
Q27004638	Biologics in dermatology: an integrated review
Q55105693	Biosimilars Have Arrived: Rituximab.
Q34107861	Biotherapy for lymphoma
Q48562037	Bispecific Antibody Armed T Cells to Target Cancer Cells.
Q38799449	Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Q33396066	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
Q39627475	Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma
Q36283067	Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas.
Q80202124	Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma
Q50926799	Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer.
Q35824964	C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma.
Q34688644	CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells
Q26749139	CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas
Q74594237	CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
Q34146556	CD20-induced B cell death can bypass mitochondria and caspase activation.
Q34999743	CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas
Q35116864	CD22 as a target of passive immunotherapy
Q35206354	CD22-directed monoclonal antibody therapy for lymphoma
Q37336918	CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential.
Q44773537	CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma
Q37082785	CD70 as a therapeutic target in human malignancies
Q55442330	Cancer Immunotherapy and the Immune Response in Follicular Lymphoma.
Q35562113	Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells
Q36387028	Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Q35070045	Cancer radioimmunotherapy
Q37453793	Cancer therapeutic antibodies come of age: targeting minimal residual disease
Q34118856	Cancer therapy with bispecific antibodies: Clinical experience.
Q36079223	Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention
Q40565585	Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes
Q53298112	Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study.
Q39034684	Challenges and opportunities for monoclonal antibody therapy in veterinary oncology.
Q37738533	Challenges in the frontline treatment of patients with chronic lymphocytic leukemia
Q33360327	Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy
Q37662198	Changing paradigms in the treatment of chronic lymphocytic leukemia
Q42910849	Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma
Q36629232	Characterization of antibody-containing vesicles shed from B-lymphoma cell lines: exposure of annexin V binding sites
Q36216991	Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy
Q42984153	Chemoimmunotherapy of chronic lymphocytic leukemia
Q34879367	Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712
Q34565132	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
Q88257828	Chemotherapy free treatment of indolent lymphoma
Q24243100	Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma
Q34430219	Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma
Q38317235	Chemotherapy-free treatment in patients with follicular lymphoma
Q73088305	Chimeric monoclonal anti-CD20 antibody (rituximab)--an effective treatment for a patient with relapsing hairy cell leukaemia
Q38787705	Chip-based platform for dynamic analysis of NK cell cytolysis mediated by a triplebody
Q37058050	Chronic alloantibody mediated rejection
Q36609259	Chronic lymphocytic leukemia: inception to cure: are we there?
Q37377662	Chronic lymphocytic leukemia: new concepts and emerging therapies
Q35382716	Chronic lymphocytic leukemia: treatment options for patients with refractory disease
Q43542617	Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
Q38888137	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus
Q33773139	Clinical applications of anti-CD20 antibodies.
Q37770555	Clinical pharmacokinetics of therapeutic monoclonal antibodies
Q34093532	Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma.
Q47213587	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
Q33984489	Clinical trials of antibody therapy
Q35561014	Clinical use of rituximab in haematological malignancies
Q34543634	Clinically useful monoclonal antibodies in treatment
Q54310740	Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjögren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway.
Q35678195	Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy
Q40135352	Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines
Q58415142	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma
Q41270773	Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas
Q35038958	Combination of chemotherapy and monoclonal antibodies for the treatment of lymphoma
Q43293479	Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type
Q64881207	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.
Q90212478	Commentary: Potential Therapeutic Consequences of an Acid-Sensing Ion Channel 1a-Blocking Antibody
Q35126259	Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma
Q35828820	Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas
Q26860800	Complement in monoclonal antibody therapy of cancer
Q39423588	Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo.
Q77378845	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma
Q37354362	Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor
Q47193015	Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy
Q52105078	Costimulatory signals distinctively affect CD20- and B-cell-antigen-receptor-mediated apoptosis in Burkitt's lymphoma/leukemia cells.
Q26775837	Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
Q35683808	Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).
Q36922528	Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment
Q34700652	Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?
Q34666779	Current treatment of follicular non-Hodgkin's lymphoma
Q36966780	Current treatment options in follicular lymphoma: science and bias
Q24634879	Current trends in management of hepatitis B virus reactivation in the biologic therapy era
Q37123705	Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer
Q39882401	Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy
Q38996881	Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma
Q37028638	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
Q37333647	Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT.
Q36692003	Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
Q33762537	Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma
Q36407174	Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo
Q37142202	Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials
Q38550992	Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma
Q38896113	Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
Q39937143	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.
Q39821890	Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies
Q36490753	Development of antibodies and chimeric molecules for cancer immunotherapy
Q36846805	Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature
Q58200855	Differentiation between non-Hodgkin's lymphoma recurrence and second primary lymphoma by VDJ rearrangement analysis
Q36695648	Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines
Q34147379	Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Q90734623	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
Q37785097	Diversity in antibody-based approaches to non-Hodgkin lymphoma
Q24642957	Do self-perpetuating B lymphocytes drive human autoimmune disease?
Q39381251	Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.
Q36577151	Drug insight: rituximab in renal disease and transplantation
Q38061647	Drug-conjugated antibodies for the treatment of cancer
Q53207213	Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
Q33363695	Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study
Q36726780	Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
Q73275289	Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia
Q81305181	Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma
Q36860483	Effect of rituximab on human in vivo antibody immune responses
Q36455017	Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment
Q35848928	Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors
Q73720613	Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia
Q78596579	Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14
Q40070987	Effects of ultrasound on apoptosis induced by anti-CD20 antibody in CD20-positive B lymphoma cells
Q50709249	Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).
Q36411549	Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis
Q38801610	Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
Q58565563	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
Q73401621	Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
Q53557477	Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma.
Q39005581	Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment.
Q37729176	Emerging biotherapies for Sjögren's syndrome
Q48192887	Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia
Q34718371	Emerging technology and future developments in flow cytometry
Q36963208	Emerging therapies for multiple sclerosis
Q38903356	Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016).
Q39926217	Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species.
Q24813078	Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice
Q37114367	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Q35605535	Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
Q35826471	Epratuzumab in non-Hodgkin's lymphomas
Q36636619	Epratuzumab in the therapy of oncological and immunological diseases
Q24624761	Eradication of melanomas by targeted elimination of a minor subset of tumor cells
Q92111649	Erythema Migrans: Course and Outcome in Patients Treated With Rituximab
Q46037539	European Society of Medical Oncology (ESMO). Hamburg, Germany. October 13-17, 2000. American Society of Hematology. San Francisco, CA. December 1-5, 2000.
Q37676785	Evolution of anti-CD20 monoclonal antibody therapeutics in oncology
Q38764077	Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting
Q36985872	Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia
Q37771248	Expanded use of rituximab in the management of non-Hodgkin lymphoma.
Q35461949	Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia
Q74201154	Expression of a functional mouse-human chimeric anti-CD19 antibody in the milk of transgenic mice
Q47312316	Expression of single-domain antibody in different systems
Q34227851	Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer.
Q33343262	Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
Q35167393	Factors predicting the response to rituximab in indolent lymphoma.
Q43808460	Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease
Q30278460	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma
Q79338067	Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity
Q44620749	FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
Q84040581	Feasibility and toxicity of concomitant radio/immunotherapy with MabThera (Rituximab®) for patients with non-Hodkin's Lymphoma: results of a prospective phase I/II study
Q38694867	Featured Article: Delivery of chemotherapeutic vcMMAE using tobacco mosaic virus nanoparticles
Q27489546	First Isolation of West Nile virus from a patient with encephalitis in the United States
Q34533552	Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
Q33424781	Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia
Q40329298	Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Q36568852	Follicular Lymphoma International Prognostic Index
Q38419117	Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study
Q98386577	Follicular lymphoma with paraneoplastic pemphigus as the first symptom: a case report and review of the literature
Q36168712	Follicular lymphoma: management options in the era of targeted therapy
Q33927978	Follicular lymphoma: still Six characters in search of an author?
Q33947861	Follicular lymphomas--a review of treatment modalities.
Q30436996	Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia
Q42106252	From Transplant to Tablets: A paradigm shift in Oncology
Q26852919	From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies
Q37784673	Front-line management of diffuse large B cell lymphoma
Q35628492	Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer
Q36897788	Fulminant Colitis Following Rituximab Therapy
Q47216941	Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy
Q38315579	GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present
Q35673900	Gene therapy for cancer: present status and future perspective
Q39591125	Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia
Q33823065	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.
Q51259489	Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance.
Q36743909	Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study
Q28088598	Harnessing the Microbiome to Enhance Cancer Immunotherapy
Q34677789	Heavy chain disease
Q26851987	Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma
Q38100784	Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma
Q35583718	Hepatitis B reactivation and rituximab in the oncology practice.
Q26830484	Hepatitis B virus reactivation with rituximab-containing regimen
Q34579836	Herpesvirus infections in organ transplant recipients
Q35854779	Heterogeneity in the multiple myeloma tumor clone.
Q41645565	Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma
Q38105625	Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
Q34223872	Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse
Q52593925	How Biophysical Forces Regulate Human B Cell Lymphomas.
Q35579475	How does B cell depletion therapy work, and how can it be improved?
Q64095781	How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin's lymphomas
Q38848737	Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors.
Q21285083	Human polyomavirus reactivation: disease pathogenesis and treatment approaches
Q34441137	Human therapeutic antibodies
Q37424092	Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis
Q48350859	Humanization and characterization of the anti-HLA-DR antibody 1D10.
Q38735872	Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach with retention of biological activity
Q90411229	Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment
Q57218959	Hématologie
Q37401659	I-Tositumomab in lymphoma.
Q38130010	Ibrutinib and novel BTK inhibitors in clinical development
Q33413834	Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Q37167336	Imaging characteristics of zinc sulfide shell, cadmium telluride core quantum dots
Q84417756	Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab
Q37474352	Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
Q33627797	Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma
Q33899097	Immunology and immunotherapy of human cancer: present concepts and clinical developments
Q37399992	Immunomodulation in the treatment of haematological malignancies
Q38051534	Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development.
Q35169138	Immunotherapy for lymphomas
Q84740271	Immunotherapy of cancer
Q36797398	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.
Q35739441	Immunotherapy of cancer: from vision to standard clinical practice
Q89626900	Immunotherapy of lymphomas
Q34085036	Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease
Q36985497	Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-dr
Q35213332	Immunotherapy with anti-CD20 compounds
Q22251059	Immunotherapy: past, present and future
Q37954336	Immunotoxins and other conjugates containing saporin-s6 for cancer therapy
Q33745138	Immunotoxins in cancer therapy
Q35237511	Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?
Q34619308	Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma
Q38987211	Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies
Q36488282	Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.
Q38408710	Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis
Q28208361	Improving the efficacy of antibody-based cancer therapies
Q38799409	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies
Q57373163	In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells
Q34526378	In vivo purging and relapse prevention following ASCT.
Q28752150	In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice
Q33668990	Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.
Q40409590	Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
Q44430286	Induction of Complete Remission of Hypoplastic Leukemia with Antithymocyte Globulin
Q47387344	Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells
Q39708039	Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion
Q33787262	Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma
Q42239906	Influenza vaccination in oncology patients
Q36830105	Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
Q52603729	Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study.
Q50090799	Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome.
Q75355864	Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma
Q36213094	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Q40561962	Innovative strategies in lymphoma therapy
Q48216426	Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence.
Q28740388	Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo
Q40069811	Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome
Q80408694	Intraocular rituximab
Q80177081	Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma
Q40632733	Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab
Q34124126	Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials
Q33395696	Investigational drugs in thrombotic thrombocytopenic purpura.
Q37667386	Investigational immunotherapeutics for B-cell malignancies
Q38434473	Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma
Q36839758	Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma
Q35614792	Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma
Q80167352	Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment?
Q53248278	Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab.
Q53271214	Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis.
Q79270320	Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma
Q36060329	Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions
Q26849243	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
Q35157616	Ligand-targeted liposomal anticancer drugs
Q28079742	Limited Stage Follicular Lymphoma: Current Role of Radiation Therapy
Q43634469	Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma
Q34470480	Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas
Q37632211	Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab
Q36614459	Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma
Q47935954	Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging: preliminary findings
Q36099232	Longitudinal risk of herpes zoster in patients with non-Hodgkin lymphoma receiving chemotherapy: A nationwide population-based study
Q52004511	Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection
Q74346082	Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma
Q33393434	Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia
Q42178052	Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.
Q26782902	Lymphoma Immunotherapy: Current Status
Q42926735	Lymphoma: a clinical view
Q61831525	Lymphomes chez l'enfant infecté par le VIH-1
Q53228301	Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma.
Q33685903	Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data
Q37158257	Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study
Q37940552	Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies
Q34340415	Management of AIDS-related non-Hodgkin's lymphomas
Q36784860	Management of indolent lymphoma: where are we now and where are we going
Q37775633	Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas
Q35859018	Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease
Q34603567	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
Q73551191	Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies
Q90322835	Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies
Q35717890	Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells
Q74049443	Metastatic gastric maltoma: a rare cause of obscure gastrointestinal bleeding
Q35213336	Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab
Q44632533	Mitoxantrone–cyclophosphamide–rituximab: an effective and safe combination for indolent NHL
Q36036378	Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.
Q35562656	Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies
Q35790781	Molecular biological design of novel antineoplastic therapies
Q24619923	Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain
Q38676578	Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future
Q35761687	Monoclonal antibodies as therapeutic agents for cancer
Q36715285	Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy
Q35029568	Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma
Q37181031	Monoclonal antibodies for cancer immunotherapy
Q34700655	Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives
Q34124115	Monoclonal antibodies in lymphoid neoplasia: principles for optimal combined therapy
Q33363981	Monoclonal antibodies in the treatment of chronic lymphocytic leukemia
Q35752823	Monoclonal antibodies in the treatment of chronic lymphoid leukemias
Q34478304	Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments
Q34576803	Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma
Q34111693	Monoclonal antibodies: versatile platforms for cancer immunotherapy
Q34236658	Monoclonal antibody therapy
Q35038955	Monoclonal antibody therapy for B-cell lymphoma
Q35038965	Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan
Q35158950	Monoclonal antibody therapy for lymphoma
Q34552428	Monoclonal antibody therapy for lymphoma: an update
Q35909297	Monoclonal antibody therapy in lymphoid leukemias
Q81189032	Monoclonal antibody therapy of cancer
Q37613872	Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia
Q42165704	Monoclonal antibody treatment of malignant lymphoma
Q37568787	Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
Q34124133	Monoclonal antibody-based therapy of lymphoid neoplasms: what's on the horizon?
Q46451633	Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease
Q73695629	Multiple complications of IVIG therapy in a patient with Guillain-Barré syndrome
Q38542034	Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.
Q36622723	Neoplastic stem cells: a novel therapeutic target in clinical oncology
Q37767703	New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.
Q27022373	New antibody approaches to lymphoma therapy
Q37852003	New antibody drug treatments for lymphoma
Q37738418	New aspects of the treatment of chronic lymphocytic leukemia
Q34261338	New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia
Q36223636	New developments in immunotherapy for non-Hodgkin's lymphoma
Q35190687	New strategies in radioimmunotherapy for lymphoma
Q38787141	New targeted therapies for malignant lymphoma based on molecular heterogeneity
Q33587396	New targets for the treatment of follicular lymphoma
Q33579636	Next generation of antibody therapy for cancer
Q36679573	Nodal Follicular Lymphomas: A Clinicopathological Study from a Tertiary Care Centre in South India
Q35179500	Non-Hodgkin lymphoma
Q84629067	Non-Hodgkin lymphoma
Q35789262	Non-Hodgkin lymphoma: an update
Q38132359	Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance
Q43139321	Non-Hodgkin's lymphoma in the elderly
Q37738497	Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma
Q37370563	Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.
Q37691759	Novel agents for B-cell non-Hodgkin lymphoma: science and the promise
Q38108836	Novel antibodies targeting immune regulatory checkpoints for cancer therapy.
Q27004436	Novel immunotherapies for hematologic malignancies
Q38827600	Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l
Q47688545	Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
Q38876219	Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma
Q39431675	Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
Q38632940	Ofatumumab for treating chronic lymphocytic leukemia: a safety profile
Q24604065	Ofatumumab: a novel monoclonal anti-CD20 antibody
Q39303346	Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia
Q35569418	One target, different effects: a comparison of distinct therapeutic antibodies against the same targets
Q35167929	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
Q55515652	Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.
Q35558322	Overview of Antibody Therapy in B-Cell Non-Hodgkin's Lymphoma
Q37058039	Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts.
Q44393916	Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma
Q55283747	Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.
Q36496173	Patient benefits of maintenance immunotherapy
Q48322740	Paul Ehrlich's magic bullet concept: 100 years of progress
Q38551684	Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review.
Q36382319	Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach
Q73288849	Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as ‘in vivo purge’ and consolidative immunotherapy following autologous stem cell transplantation
Q35992515	Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma
Q77134775	Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
Q33422543	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies
Q64116907	Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)
Q79177549	Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma
Q33399704	Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
Q36897238	Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
Q33386521	Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
Q33374978	Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation
Q36058502	Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
Q49330513	Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).
Q53406277	Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.
Q44059739	Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas
Q42355121	Physicochemical Evaluation of Lyophilized Formulation of p-SCN-Bn-DOTA- and p-SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy
Q34124121	Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma
Q30419228	Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma
Q27002505	Polymer-drug conjugates: origins, progress to date and future directions
Q37369319	Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.
Q90285434	Position of Scientific Oncological Societies Towards Biosimilar Antibodies
Q39414818	Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL.
Q36074287	Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options
Q38273851	Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance
Q61455994	Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy
Q39124225	Precision medicine needs randomized clinical trials
Q36832137	Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies
Q39117341	Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
Q42183011	Predicting success or failure of immunotherapy for cancer: insights from a clinically applicable mathematical model.
Q39306456	Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity
Q34669139	Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma
Q91745562	Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma
Q24646477	Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy
Q36791086	Primary extraosseous Ewing sarcoma of the lung in children
Q33817252	Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement
Q28243883	Principles of maintenance therapy
Q35970489	Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation
Q37269115	Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering
Q47449201	Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients
Q43841306	Progress in CLL, chemotherapy, antibodies and transplantation
Q73401113	Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma
Q53246385	Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
Q77406551	Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG
Q36115663	Prolymphocytic leukemia
Q33929477	Promising approaches in acute leukemia
Q38855416	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation
Q33369574	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura
Q34728463	Protein therapeutics: a summary and pharmacological classification
Q44163481	Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma.
Q36423833	Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia
Q33745965	Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay
Q37158679	R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature
Q36776358	RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY.
Q35736289	Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography
Q34631795	Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab
Q38017790	Radioimmunotherapy in mantle cell lymphoma.
Q36426877	Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
Q35927598	Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen
Q37969746	Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'.
Q46529502	Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience
Q34696315	Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma
Q79077175	Radioimmunotherapy with131I-Rituximab: What We Know and What We Don't Know
Q55709954	Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
Q37579292	Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma
Q38189541	Radiolabeling strategies for tumor-targeting proteinaceous drugs
Q47830676	Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
Q37380415	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
Q36211619	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Q36443141	Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
Q41636230	Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).
Q30417730	Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia
Q36095143	Rapid-infusion rituximab in lymphoma treatment: 2-year experience in a single institution
Q46113809	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Q37079029	Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Q73926704	Re-treatment of relapsed indolent B-cell lymphoma with rituximab
Q37798175	Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy
Q42076420	Real time analysis of binding between Rituximab (anti-CD20 antibody) and B lymphoma cells
Q47188177	Real-Time t(14;18)(q32;q21) PCR assay combined with high-resolution capillary electrophoresis: a novel and rapid approach that allows accurate quantitation and size determination of bcl-2/JH fusion sequences
Q36765440	Recent advances and current challenges in tumor immunology and immunotherapy.
Q33781006	Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas
Q31166188	Recombinant antibodies for the diagnosis and treatment of cancer
Q34295821	Recombinant immunotoxins in targeted cancer cell therapy
Q46031680	Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
Q36529941	Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
Q38453207	Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study
Q89835028	Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature
Q61863467	Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes
Q39534447	Refractory Sweet's syndrome successfully treated with rituximab
Q35484992	Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.
Q38911219	Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia
Q28366177	Remission of cold hemagglutinin disease induced by rituximab therapy
Q91148338	Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications
Q41883282	Repeated B cell depletion in treatment of refractory systemic lupus erythematosus
Q30395200	Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host
Q41740650	Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates
Q43837378	Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy
Q57636827	Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment
Q48367614	Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.
Q74234782	Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma
Q74234772	Risk factors for side effects during first infusion of rituximab-definition of a low risk group
Q40097140	Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.
Q33706729	Rituximab
Q40590761	Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.
Q44148376	Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study
Q35567244	Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Q33899917	Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
Q41215683	Rituximab administration and reactivation of HBV.
Q35988820	Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study
Q37879578	Rituximab and minimal change nephrotic syndrome: a therapeutic option
Q40409351	Rituximab and other emerging monoclonal antibody therapies for lymphoma
Q40750834	Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients
Q38100232	Rituximab biosimilars
Q36787584	Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
Q33365619	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura
Q35848116	Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Q30370665	Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.
Q30277158	Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402
Q33357445	Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome
Q34687563	Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation
Q33385079	Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease
Q39360775	Rituximab for the treatment of follicular lymphoma.
Q41241909	Rituximab for the treatment of patients with chronic lymphocytic leukemia
Q57753910	Rituximab for the treatment of type II mixed cryoglobulinemia
Q49866575	Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.
Q37162867	Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
Q51733779	Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
Q46675870	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Q35206360	Rituximab in B-cell chronic lymphocytic leukemia
Q84497949	Rituximab in chronic lymphocytic leukemia
Q33375262	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma
Q44551813	Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study
Q33764062	Rituximab in indolent lymphomas
Q81440341	Rituximab in mixed cryoglobulinemia: increased experience and perspectives
Q37670299	Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome
Q47196522	Rituximab in the management of acute lymphoblastic leukemia
Q33621041	Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
Q41925899	Rituximab in the treatment of non-Hodgkin's lymphoma
Q53580474	Rituximab in the treatment of rheumatoid arthritis.
Q74213268	Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL
Q64123705	Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database
Q35113379	Rituximab maintenance in follicular lymphoma patients
Q36913244	Rituximab maintenance in indolent lymphoma: indications and controversies
Q34449805	Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value
Q37738492	Rituximab maintenance therapy in follicular lymphoma
Q36496164	Rituximab maintenance therapy in indolent NHL: a clinical review
Q37930456	Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?
Q38050339	Rituximab maintenance versus retreatment in follicular lymphoma
Q33375317	Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
Q54506169	Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma.
Q36216264	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
Q80335952	Rituximab therapy for life-threatining immune hemolytic anemia in a liver tranplant recipient: a case report
Q37412829	Rituximab therapy for membranous nephropathy: a systematic review
Q73374303	Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity
Q34362660	Rituximab therapy in idiopathic membranous nephropathy: a 2-year study
Q36832102	Rituximab therapy in malignant lymphoma
Q40342453	Rituximab tolerability when given before or after CHOP.
Q53210304	Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series.
Q33370325	Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus
Q31032919	Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity
Q39121466	Rituximab treatment of myasthenia gravis: A systematic review
Q91605973	Rituximab use for lymphoplasmacytic lymphoma during continuous renal replacement therapy
Q33340124	Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia
Q37720886	Rituximab-associated neutropenia
Q44161639	Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia
Q36167378	Rituximab-based treatment, HCV replication, and hepatic flares
Q88020335	Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis
Q55050510	Rituximab-induced Acute Thrombocytopenia in a Patient with Follicular Lymphoma: A Case Report and Review of the Literature.
Q36413919	Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma
Q33401452	Rituximab-induced thrombocytopenia: a cohort study.
Q47913342	Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma
Q37781697	Rituximab: a review of dermatological applications
Q34124932	Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma
Q34186569	Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
Q83362579	Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
Q73793902	Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?
Q37875060	Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma
Q37984551	Rituximab: current status as therapy for malignant and benign hematologic disorders
Q24607358	Rituximab: mechanism of action
Q34462378	Rituximab: mechanisms and applications
Q34386171	Rituximab: perspective on single agent experience, and future directions in combination trials
Q36218799	Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia
Q34574147	Role of rituximab in first-line treatment of chronic lymphocytic leukemia
Q41439263	Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study
Q33405150	Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab
Q42399897	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi
Q88908630	Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial
Q38100787	Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia
Q44431114	Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma
Q35794369	Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
Q36496168	Safety of rituximab maintenance therapy in follicular lymphomas
Q49501113	Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.
Q34186583	Salvage therapy for refractory or relapsed acute lymphocytic leukemia
Q36244295	Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system
Q93111300	Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma
Q37585103	Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?
Q88119334	Selection and Characterization of Single-Stranded DNA Aptamers Binding Human B-Cell Surface Protein CD20 by Cell-SELEX
Q38042439	Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?
Q59308861	Septic polyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment
Q37622471	Serum autoantibodies as biomarkers for early cancer detection
Q55115766	Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.
Q43136160	Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis
Q33691650	Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Q73597520	Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion
Q39991731	Shining light on nuclear-targeted therapy using gold nanostar constructs
Q37440061	Siglecs as targets for therapy in immune-cell-mediated disease
Q33745167	Signaling antibodies in cancer therapy
Q48276545	Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing
Q73330865	Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network
Q33718809	Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era.
Q36200735	Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas
Q78445240	Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study
Q28472420	Statins impair antitumor effects of rituximab by inducing conformational changes of CD20
Q37599672	Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms
Q40519355	Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia.
Q34750560	Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.
Q35915790	Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
Q33376272	Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma
Q43842261	Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab
Q33347534	Successful treatment of a patient with hairy cell leukemia and pentostatin‐induced autoimmune thrombocytopenia with rituximab
Q37211086	Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients
Q74269965	Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab
Q74447937	Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody
Q33357593	Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura
Q40797481	Susceptibility of B-cell lymphoma to human antibodies encoded by the V4-34 gene
Q37732218	Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide
Q33336433	Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Q33338419	Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.
Q40779596	Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Q90401110	Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
Q91522807	T cell-engaging therapies - BiTEs and beyond
Q36194235	TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas
Q36349687	Tailoring antibodies for radionuclide delivery
Q41759590	Targeted Therapy with Rituximab in Felty's Syndrome: A Case Report.
Q42077750	Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells
Q33788697	Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma
Q38058816	Targeted drug delivery for cancer therapy: the other side of antibodies
Q36489856	Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas
Q35208663	Targeted therapies for the treatment of cancer
Q37431603	Targeted therapy for chronic lymphocytic leukemia
Q36158708	Targeted therapy for epithelial ovarian cancer
Q36108610	Targeted therapy for hematologic malignancies
Q37430243	Targeted therapy in chronic lymphocytic leukemia: past, present, and future
Q37766121	Targeted treatment and new agents in diffuse large B cell lymphoma
Q24681992	Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
Q37302795	Targeting the B cell in vasculitis
Q50687660	The 41st annual meeting of the American Society of Hematology. New Orleans, LA. December 3-7, 1999.
Q64999117	The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance.
Q92668984	The Fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III
Q34021580	The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals
Q46801651	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia
Q36787532	The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Q36792745	The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?
Q34470502	The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
Q40563800	The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.
Q36970950	The curability of follicular lymphoma
Q46072308	The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis
Q45366697	The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy
Q33683956	The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
Q37754083	The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials
Q24617708	The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia
Q26801603	The evolution within us
Q77167914	The expanding frontier of radioimmunotherapy of relapsed Non-hodgkin's lymphoma
Q38182645	The expanding role of therapeutic antibodies
Q36331576	The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma
Q24681044	The future of biologic agents in the treatment of Sjögren's syndrome
Q35525404	The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
Q36402637	The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
Q33774368	The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients
Q36937772	The management of posttransplant lymphoproliferative disorder
Q46965117	The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy
Q45803486	The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
Q38124009	The optimal management of follicular lymphoma: an evolving field
Q51904511	The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation.
Q33742186	The problem of anti-pig antibodies in pig-to-primate xenografting: current and novel methods of depletion and/or suppression of production of anti-pig antibodies
Q34486116	The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience
Q38069595	The role of monoclonal antibodies in the treatment of lymphomas
Q41695080	The role of novel immunotherapies in non-Hodgkin lymphoma
Q26824280	The role of rituximab in adults with warm antibody autoimmune hemolytic anemia
Q39018189	The safety profile of monoclonal antibodies for chronic lymphocytic leukemia
Q34510030	The spectrum of use of rituximab in chronic lymphocytic leukemia
Q38215613	The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.
Q27693293	Theranostic applications of antibodies in oncology.
Q35908498	Therapeutic antibodies against cancer
Q35909323	Therapeutic idiotype vaccines for non-Hodgkin's lymphoma
Q52858060	Therapeutic monoclonal antibodies in oncology.
Q38478878	Therapeutic potential and challenges of natural killer cells in treatment of solid tumors
Q34570753	Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
Q38227030	Therapeutic vaccines for cancer: an overview of clinical trials
Q33944243	Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways
Q36057860	Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies
Q36894785	Therapy of gastric mucosa associated lymphoid tissue lymphoma
Q36623092	Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen
Q36457298	Therapy of newly diagnosed follicular lymphoma
Q35106176	Therapy of non-Hodgkin's lymphoma.
Q54559642	Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion.
Q47365893	Title: Rituximab: A Benchmark in the Development of Chemotherapy-free Treatment Strategies for Follicular Lymphomas.
Q38409715	Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.
Q36253608	Toll-like receptors in tumor immunotherapy
Q96641056	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
Q37552019	Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy
Q48354783	Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?
Q37318762	Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy
Q34133623	Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
Q43069450	Treatment of IgM antibody associated polyneuropathies using rituximab
Q80432823	Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab
Q73833684	Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody
Q36276360	Treatment of elderly cancer patients with chemotherapy
Q37280915	Treatment of follicular lymphoma: current status
Q35818224	Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone
Q33830194	Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial
Q35206348	Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab
Q37419728	Treatment of lymphoma with adoptively transferred T cells.
Q39410091	Treatment of membranous nephropathy: time for a paradigm shift
Q73165992	Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child
Q37912214	Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?
Q40553648	Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy
Q37652790	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
Q36038408	Trial Watch: Monoclonal antibodies in cancer therapy
Q43104064	Trial Watch: Radioimmunotherapy for oncological indications
Q26993238	Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
Q56932681	Trial watch: Monoclonal antibodies in cancer therapy
Q73986142	Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: a new role for TNF alpha?
Q34834369	Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo
Q34038839	Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma
Q41904274	Tumour inflammatory response: adding fuel to the fire?
Q35780034	Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
Q38416175	Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas
Q37672125	Understanding and circumventing resistance to anticancer monoclonal antibodies.
Q38871098	Unintended Immunological Consequences of Biologic Therapy.
Q36490763	Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo
Q50105551	Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.
Q33406478	Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis
Q37913356	Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders
Q35579499	Update on rituximab
Q33915986	Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma
Q78661949	Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients
Q95272848	Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature
Q38769922	Use of polyclonal/monoclonal antibody therapies in transplantation
Q38737643	Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre
Q33980153	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
Q40037319	Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases.
Q39043404	Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update
Q30330481	Vaccine therapies for non-Hodgkin's lymphoma.
Q34762576	Variation in gene expression patterns in follicular lymphoma and the response to rituximab
Q33388543	Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects
Q42197783	Visceral disseminated varicella zoster virus infection after rituximab treatment for granulomatosis with polyangiitis.
Q44421377	Waldenstrom's macroglobulinemia: A retrospective analysis of 40 patients from 1972 to 2001
Q36535485	Yttrium 90 ibritumomab tiuxetan in lymphoma
Q37586857	Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects
Q81399764	[Antibodies against cancer]
Q82543949	[Cutaneous large B-cell lymphoma of the leg]
Q82543603	[Cutaneous marginal zone B-cell lymphoma treated with rituximab]
Q80098830	[Designer-drugs in tumor treatment]
Q75410139	[Role of anti-CD20 monoclonal antibody in association with immunomodulatory agents]
Q81588936	[Treatment of hematological malignancies with monoclonal antibodies]
Q53311529	[Tumor stem cell research - basis and challenge for diagnosis and therapy].

P356	DOI	10.1200/JCO.1998.16.8.2825
P698	PubMed publication ID	9704735

P50	author	Brian K Link	Q61054699
P2093	author name string	R Levy
		M E Williams
		V Jain
		D Shen
		M S Czuczman
		P McLaughlin
		F Cabanillas
		A D Ho
		J Lister
		I Bence-Bruckler
		C A White
		A J Grillo-López
		M R Heyman
		K Wey
		B K Dallaire
P433	issue	8
P407	language of work or name	English	Q1860
P921	main subject	antibody	Q79460
		patient	Q181600
		rituximab	Q412323
		monoclonal antibody	Q422248
P304	page(s)	2825-2833
P577	publication date	1998-08-01
P1433	published in	Journal of Clinical Oncology	Q400292
P1476	title	Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
P478	volume	16

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

scientific article

Reverse relations